Amgen discovers, develops, manufactures and delivers human therapeutics. Co.'s primary products are Neulasta®, a pegylated protein, based on the Filgrastim molecule, and NEUPOGEN®, a recombinant-methionyl human granulocyte colony-stimulating factor, both of which stimulate the production of neutrophils; Enbrel®, an inhibitor of tumor necrosis factor, a substance that plays a role in inflammatory diseases; Aranesp® and EPOGEN®, erythropoiesis-stimulating agents that stimulate the production of red blood cells; and XGEVA®/Prolia®, two products that contain the same active ingredient but which are approved for different indications, patient populations, doses and frequencies of administration.
AMGN — Key Stats (updated Monday, March 3, 10:17 AM)
Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Service. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20
minutes; ETF data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.